Re-engineering Cellular Medicine

A cell engineering company harnessing the power of genetics to replace defective cells

Technology Overview

Induced Pluripotent stem cells (iPSCs) are derived from somatic cells by temporary expression of four transcription factors, also referred to as the Yamanaka Factors. iPSCs share all the characteristics of embryonic stem cells. As illustrated, iPSCs have the ability to differentiate into all human cell types.

Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients

To deliver these cells we focus on two distinct methodologies

Personalized Autologous Approach
Patient-specific therapy
Allogeneic Approach
Universal Therapy

Join our team

Join us as we re-engineer cellular medicine.